06622.HK
Zhaoke Ophthalmology Limited
HKSE · Healthcare · Biotechnology · CN
HKD 2.53
+1.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 70.1M | 31.1M | 69.3M | 18.8M | — |
| Cost of Revenue | 88.1M | 63.7M | 17.5M | 4.5M | — |
| Gross Profit | (18.0M) | (32.6M) | 51.8M | 14.2M | — |
| Operating Expenses | |||||
| R&D Expense | 355.6M | 132.5M | 203.7M | 333.1M | 296.4M |
| SG&A Expense | 160.6M | 36.9M | 134.3M | 43.2M | 48.1M |
| General & Admin Expense | 55.7M | 16.2M | 70.8M | 23.1M | 18.1M |
| Selling & Marketing Expense | 55.7M | 20.7M | 63.5M | 20.0M | 29.9M |
| Other Expenses | 119.5M | 64.5M | (58.2M) | 14.6M | 60.5M |
| Total Operating Expenses | 635.8M | 233.8M | 279.8M | 390.8M | 405.0M |
| Cost and Expenses | 723.9M | 297.6M | 297.3M | 395.3M | 405.0M |
| Operating Income (EBIT) | (653.8M) | (266.4M) | (228.0M) | (376.6M) | (404.2M) |
| Non-Operating | |||||
| Interest Income | 70.5M | 43.2M | 75.2M | 77.4M | 30.4M |
| Interest Expense | 14.0M | 8.8M | 9.5M | 7.9M | 3.1M |
| Net Interest Income | 56.6M | 34.4M | 65.7M | 69.5M | 27.3M |
| Other Non-Op Income/Expense | 161.9M | 62.8M | (9.5M) | (7.9M) | (3.1M) |
| Non-Operating Income (excl Interest) | (49.7M) | — | 56.9M | — | 8.2M |
| EBT (Pre-Tax Income) | (491.9M) | (203.6M) | (237.5M) | (384.5M) | (407.3M) |
| Income Tax Expense | — | — | — | 550.0K | 3.1M |
| Bottom Line | |||||
| Net Income | (491.9M) | (203.6M) | (237.5M) | (385.0M) | (407.3M) |
| Earnings from Cont. Ops | (491.9M) | (203.6M) | (237.5M) | (385.0M) | (407.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (491.9M) | (203.6M) | (237.5M) | (385.0M) | (407.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.90) | (HK$0.37) | (HK$0.43) | (HK$0.71) | (HK$0.75) |
| Diluted EPS | (HK$0.90) | (HK$0.37) | (HK$0.43) | (HK$0.71) | (HK$0.75) |
| Revenue Per Share | HK$0.13 | HK$0.06 | HK$0.13 | HK$0.03 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 548.5M | 546.9M | 546.1M | 543.9M | 542.2M |
| Diluted Shares Outstanding | 548.5M | 546.9M | 546.1M | 543.9M | 542.2M |
| Profitability Metrics | |||||
| EBITDA | (512.9M) | (215.4M) | (251.2M) | (327.9M) | (384.6M) |
| D&A | 91.1M | 51.0M | 33.7M | 48.7M | 27.8M |
| EBIT | (604.0M) | (266.4M) | (284.9M) | (376.6M) | (412.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026